Latest Market Entry News

Botanix Pharmaceuticals has received an Intention to Grant from the European Patent Office for a patent protecting its Sofdra applicator technology, potentially extending exclusivity in Europe until 2039.

Swift TV has landed a second multi-site hospitality contract, expanding its footprint in premium Western Australian accommodation and reinforcing its recurring revenue model.

ReNerve Limited has secured regulatory approval to market its flagship NervAlign Nerve Cuff in Indonesia, marking a major step in its Asia-Pacific expansion and unlocking access to one of the region’s largest nerve repair markets.

Germany’s Hesse State Office has issued new GMP guidance that questions the viability of fragmented medicinal cannabis supply chains, reinforcing ECS Botanics’ integrated manufacturing approach and potentially tightening market supply.

Orthocell has secured a strategic foothold in Thailand's $84 million nerve repair sector by appointing MediTime as exclusive Remplir distributor, leveraging established clinical networks to accelerate market penetration.

Gold Hydrogen gears up for critical Ramsay Project flow testing of Natural Hydrogen and Helium, while advancing a green methanol feasibility study with Mitsubishi Gas Chemical.

Intelligent Monitoring Group (ASX:IMB) has agreed to acquire ADT's UK residential security business for GBP 180 million, doubling its scale and entering a fast-growing market. The deal is expected to add 40% to EPS on a pro forma basis without requiring external equity.

Iperion Limited trimmed its net loss to $294,595 for the year to March 2026, aided by waived manufacturing fees and waived licence performance targets, while securing a $250,000 loan facility to underpin ongoing development of its antimicrobial Pathoglaze product.

AnteoTech has shipped a 20-litre sample of its new Anteo C primer coating additive to a South Korean manufacturer, marking a key step from lab trials to manufacturing-scale evaluation in lithium-ion battery production.

Sparc Technologies has unveiled SparcESTM, a graphene additive range designed for electrostatic and conductive coatings, aiming to disrupt a $1.65 billion market driven by data centres, semiconductors, and EV battery manufacturing.

Clarity Pharmaceuticals will present compelling data at EANM 2026 demonstrating its 64Cu-SAR-bisPSMA imaging agent’s superior detection of prostate cancer recurrence and promising therapeutic results from 67Cu-SAR-bisPSMA in advanced disease.

TruScreen Group has completed a substantially oversubscribed NZ$2.9 million rights issue, boosting total capital raised to over NZ$4 million. The funds are set to support the company’s global expansion in cervical screening technology.